

Supplementary Table 4. Risk of major cardiovascular events per 1-SD changes in on-treatment lipid parameters according to risk group and LDL-C levels

Variable	Moderate risk group			High risk group			P for interaction
	Adjusted HR (model A) ^a	Adjusted HR (model B) ^b	Adjusted HR (model C) ^c	Adjusted HR (model A) ^a	Adjusted HR (model B) ^b	Adjusted HR (model C) ^c	
(A) LDL-C <100 mg/dL							
LDL-C	1.17 (0.83–1.65)	1.37 (0.96–1.96)	1.41 (0.99–2.01)	1.19 (1.02–1.39)	1.31 (1.11–1.55)	1.34 (1.13–1.58)	0.789
TG	0.94 (0.66–1.33)	0.91 (0.62–1.32)	0.90 (0.61–1.33)	1.15 (1.01–1.31)	1.12 (0.98–1.29)	1.13 (0.98–1.29)	0.285
HDL-C ^d	0.96 (0.69–1.33)	0.93 (0.68–1.28)	0.93 (0.67–1.28)	1.32 (1.11–1.56)	1.25 (1.04–1.50)	1.24 (1.02–1.50)	0.124
Non-HDL-C	1.05 (0.76–1.45)	1.18 (0.84–1.66)	1.25 (0.87–1.78)	1.31 (1.13–1.52)	1.36 (1.18–1.57)	1.47 (1.22–1.77)	0.395
(B) 70 ≤ LDL-C <100 mg/dL							
LDL-C	1.65 (0.65–4.21)	2.11 (0.73–6.06)	2.04 (0.71–5.89)	1.81 (1.16–2.81)	1.83 (1.16–2.87)	1.85 (1.18–2.92)	0.844
TG	1.12 (0.68–1.84)	1.95 (1.06–3.59)	1.91 (1.01–3.60)	1.23 (0.99–1.53)	1.20 (0.96–1.49)	1.16 (0.92–1.45)	0.766
HDL-C ^d	0.91 (0.59–1.39)	1.22 (0.75–1.99)	1.18 (0.73–1.91)	1.38 (1.07–1.77)	1.38 (1.05–1.80)	1.36 (1.04–1.78)	0.173
Non-HDL-C	1.15 (0.65–2.06)	1.88 (0.93–3.77)	2.04 (0.85–4.91)	1.56 (1.20–2.04)	1.51 (1.16–1.98)	1.72 (1.19–2.48)	0.487
(C) LDL-C <70 mg/dL							
LDL-C	1.09 (0.51–2.31)	1.44 (0.61–3.41)	1.53 (0.62–3.77)	1.01 (0.72–1.40)	1.12 (0.79–1.59)	1.15 (0.81–1.64)	0.673
TG	0.78 (0.45–1.34)	0.75 (0.41–1.38)	0.82 (0.44–1.55)	1.15 (0.97–1.36)	1.12 (0.94–1.34)	1.10 (0.92–1.32)	0.170
HDL-C ^d	1.02 (0.61–1.70)	0.79 (0.45–1.38)	0.73 (0.41–1.30)	1.31 (1.04–1.66)	1.18 (0.93–1.51)	1.13 (0.88–1.45)	0.388
Non-HDL-C	0.80 (0.43–1.49)	0.89 (0.43–1.83)	0.97 (0.39–2.43)	1.24 (0.97–1.59)	1.25 (0.99–1.58)	1.44 (1.003–2.06)	0.270
(D) 55 ≤ LDL-C <70 mg/L							
LDL-C	0.23 (0.02–3.53)	0.07 (0.001–4.70)	0.04 (<0.01–3.39)	1.45 (0.41–5.09)	1.57 (0.41–6.07)	1.74 (0.45–6.82)	0.101
TG	0.94 (0.48–1.82)	1.39 (0.62–3.14)	1.48 (0.62–3.55)	1.19 (0.92–1.53)	1.07 (0.84–1.36)	1.04 (0.81–1.35)	0.847
HDL-C ^d	1.17 (0.57–2.38)	0.78 (0.29–2.09)	0.80 (0.30–2.16)	1.50 (1.05–2.14)	1.41 (0.96–2.06)	1.36 (0.92–2.01)	0.437
Non-HDL-C	0.79 (0.30–2.09)	1.44 (0.44–4.65)	2.11 (0.22–20.44)	1.38 (0.96–1.97)	1.19 (0.83–1.70)	1.43 (0.73–2.80)	0.452
(E) LDL-C <55 mg/dL							
LDL-C	1.16 (0.26–5.30)	1.77 (0.21–14.67)	1.37 (0.15–12.82)	1.12 (0.61–2.07)	1.18 (0.62–2.23)	1.21 (0.63–2.32)	0.413
TG	0.60 (0.23–1.55)	0.20 (0.04–0.96)	0.13 (0.02–0.98)	1.16 (0.92–1.46)	1.61 (0.89–1.52)	1.17 (0.88–1.56)	0.185
HDL-C ^d	0.83 (0.38–1.82)	0.44 (0.15–1.33)	0.46 (0.14–1.51)	1.20 (0.89–1.61)	1.05 (0.78–1.42)	1.02 (0.75–1.40)	0.291
Non-HDL-C	0.58 (0.19–1.76)	0.10 (0.01–0.84)	0.13 (0.01–1.58)	1.33 (0.92–1.92)	1.37 (0.91–2.07)	1.62 (0.86–3.07)	0.056

The SD for lipid parameters are 0.46 for LDL-C, 0.83 for TG, 0.33 for HDL-C, and 0.54 for non-HDL-C. The incidence of MACE in each subgroup and *P* for interactions between (B) & (C) and (D) & (E) are presented as separate tables on the next page.

SD, standard deviation; LDL-C, low-density lipoprotein cholesterol; HR, hazard ratio; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol.

^aAdjusted for age and sex, ^bAdjusted for model A plus waist circumference, mean fasting blood glucose, alcohol consumption, physical activity, duration of statin therapy, and concurrent medications (antihypertensive agents by class, antidiabetic agents by class, ant-thrombotic agents, fenofibrate, and omega-3 fatty acids), ^cAdjusted for model B plus other on-treatment lipid parameters, ^dHR per 1-SD decrease of HDL-C.